Efthymiou, MariaMackie, Ian JLane, Philip JAndrade, DanieliWillis, RohanErkan, DorukSciascia, SavinoKrillis, StevenBison, ElisaBorges Galhardo Vendramini, MargareteRomay-Penabad, ZurinaQi, MiaoTektonidou, MariaUgarte, AmaiaChighizola, CeciliaBelmont, H MichaelAguirre, Maria AngelesJi, LanlanBranch, D Warede Jesus, GuilhermeFortin, Paul RAndreoli, LauraPetri, MichelleCervera, RicardRodriguez, EstherKnight, Jason SAtsumi, TatsuyaVega, JoannSevim, EcemBertolaccini, Maria LauraPengo, VittorioCohen, Hannah2023-01-252023-01-252019-07-25Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, et al. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. J Thromb Haemost. 2019 Dec;17(12):2069-2080http://hdl.handle.net/10668/14344Variability remains a challenge in lupus anticoagulant (LA) testing. To validate LA test performance between Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core laboratories and examine agreement in LA status between Core and local/hospital laboratories contributing patients to this prospective registry. Five Core laboratories used the same reagents, analyzer type, protocols, and characterized samples for LA validation. Non-anticoagulated registry samples were retested at the corresponding regional Core laboratories and anticoagulated samples at a single Core laboratory. Categorical agreement and discrepancies in LA status between Core and local/hospital laboratories were analyzed. Clotting times for the reference/characterized plasmas used for normalized ratios were similar between Core laboratories (CV Laboratories can achieve good agreement in LA performance by use of the same reagents, analyzer type, and protocols. The standardized Core laboratory results underpin accurate interpretation of APS ACTION clinical data.enRussell's viper venom timeAntiphospholipid antibodiesAntiphospholipid syndromeLupus anticoagulantThrombosisAnticoagulantsAntiphospholipid syndromeBiomarkersClinical trials as topicDatabases, factualHumansLaboratory proficiency testingLupus coagulation inhibitorObserver variationPredictive value of testsProspective studiesProthrombin timeRegistriesReproducibility of resultsSerologic testsResearch article31364274open accessAnticoagulantesBases de datos factualesBiomarcadoresEnsayos de aptitud delaboratoriosInhibidor de coagulación del lupusPruebas serológicasSíndrome antifosfolípidoTiempo de protrombina10.1111/jth.145961538-7836https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jth.14596